The stock of Biostar Pharmaceuticals Incorporated (NASDAQ:BSPM) registered a decrease of 43.09% in short interest. BSPM’s total short interest was 7,000 shares in April as published by FINRA. Its down 43.09% from 12,300 shares, reported previously. With 4,800 shares average volume, it will take short sellers 2 days to cover their BSPM’s short positions. The short interest to Biostar Pharmaceuticals Incorporated’s float is 0.4%. The stock decreased 6.37% or $0.12 on April 11, hitting $1.75. About 3,449 shares traded hands. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) has declined 58.26% since September 2, 2015 and is downtrending. It has underperformed by 63.33% the S&P500.
Biostar Pharmaceuticals, Inc. is a holding company. The company has a market cap of $3.73 million. The Firm through its wholly owned subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar) and its variable interest entities (VIEs) Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan) develops, makes and markets pharmaceutical products for a variety of diseases and conditions in the People’s Republic of China (PRC or China). It has 4.17 P/E ratio. The Firm offers over-the-counter (OTC) products and prescription pharmaceuticals.
The institutional sentiment decreased to 0.33 in 2015 Q3. Its down 1.67, from 2 in 2015Q2. The ratio dropped, as 2 funds sold all Biostar Pharmaceuticals Inc shares owned while 1 reduced positions. 0 funds bought stakes while 1 increased positions. They now own 723,239 shares or 7.12% less from 778,656 shares in 2015Q2.
Iowa State Bank holds 0.01% of its portfolio in Biostar Pharmaceuticals Inc for 12,384 shares. Bank Of America Corp De owns 1,000 shares or 0% of their US portfolio. Moreover, California Public Employees Retirement System has 0% invested in the company for 14,118 shares. The New York-based Morgan Stanley has invested 0% in the stock. Renaissance Technologies Llc, a New York-based fund reported 695,570 shares.
Biostar Pharmaceuticals Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.